Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company leveraging proprietary non-viral gene engineering technologies to create life-saving therapeutics, today announced it will present preclinical research findings during the Society for Immunotherapy of Cancer (SITC) 34th Annual Meeting on its lead allogeneic product candidate, P-BMCA-ALLO1, in multiple myeloma.
November 5, 2019
· 2 min read